Gabapentin tablets (600 mg and 800 mg) are approved for adjunctive therapy in the treatment of partial seizures of epilepsy and postherpetic neuralgia. This product is the generic equivalent of Neurontin. For more information, contact Alpharma Inc. at 800-638-9096 or…
Apotex Inc (Weston, Ontario, Canada), has introduced its oral gabapentin generic. In prescription strengths of 600 mg and 800 mg, gabapentin is approved for use as adjunctive therapy for patients with epilepsy and for the treatment of postherpetic neuralgia.
Related Results
GabapentinGabapentin withdrawalIVAX Launches Gabapentin CapsulesBattle commences on generic…
MENLO PARK, Calif. — Depomed, Inc. (Nasdaq:DEPO) announced today that results from two studies of Gabapentin GR support the ability of its improved, extended release formulation to achieve dose-proportional absorption of the pain drug, gabapentin. Gabapentin GR extended release tablets are in development for the treatment of postherpetic neuralgia (PHN), a long lasting pain condition caused by nerve dam…
In mid-January, the FDA was close to a decision on pending applications for a generic form of Neurontin (gabapentin), based on a federal court’s complicated patent decision.The Washington, D.C., federal court directed the FDA to accept the ANDA submitted by Purepac, which is eligible for 180 days of exclusivity as the first sponsor. TorPh…
M2 PRESSWIRE-25 April 2007-Biotech News: Shareholders alert for Xenoport, Inc.(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:25042007 Shareholders alert for Xenoport, Inc. (NASDAQ:XNPT) Xenoport, Inc. operates as a biopharmaceutical company in the United States. It focuses on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutri…
Depomed, Inc. (NASDAQ:DEPO) announced today that it has received a
Notice of Allowance from the U.S. Patent and Trademark Office for U.S.
patent application number 10/280,309.
Paul B. Simboli, Depomed’s director of Intellectual Property,
noted that the patent contains claims directed to methods for treating
neuropathic pain and claims related to methods for delivering
compounds via specific dosage form technologies.
…
WASHINGTON INSIDER
Most Popular
3 Questions No Job Seeker Ever Wants To Be Asked?
Public Speaking: 7 Secrets Of Great Public Speakers
13 Job Interview Mistakes To Avoid
5 Regular Mistakes In Public Speaking
10 Jobs That Pay $30 An Hour
The Division of Drug Marketing, Advertising, and Communications (DDMAC) has ordered Pfizer Inc to discontinue use of Neurontin (gabapentin) promoti…
NEW YORK — Pfizer Inc said today that an appeals court has overturned a lower court ruling that several generic manufacturers did not infringe the company’s patent for stabilized formulations of gabapentin, the active ingredient in Neurontin.
The Court of Appeals for the Federal Circuit r…
